Sanj K. Patel, President & CEO at SYNAGEVA BIOPHARMA CORP (GEVA), sold 100,000 shares at $47.91 ($4.8M) on 2013-07-26, disclosed to the SEC on 2013-07-29.
Scheduled sale ($4.8M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $48.73 | 14,711 | $717K | 14.9% |
| 2 | $47.91 | 52,190 | $2.5M | 52.1% |
| 3 | $48.31 | 17,204 | $831K | 17.3% |
| 4 | $47.39 | 15,895 | $753K | 15.7% |
| Total | $48.02 avg | 100,000 | $4.8M | 100% |
| Filing → |
| KNSA | SELL | 2026-04-08 | $364K | — | Filing → |
| KNSA | SELL | 2025-10-22 | $20.0M | — | Filing → |
| KNSA | SELL | 2025-05-28 | $4.6M | — | Filing → |